Welcome to our dedicated page for Ekso Bionics SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ekso Bionics Holdings Inc. filings document material-event disclosures, financing arrangements, governance actions, capital-structure changes, and operating results for an exoskeleton technology issuer. The company’s Form 8-K disclosures include financial results, material agreements, shareholder voting matters, and security-structure information tied to preferred stock, warrants, and other corporate actions.
Regulatory filings also cover a private placement of Series B Convertible Preferred Stock and warrants, a secured term loan involving subsidiary Ekso Bionics, Inc. as guarantor, equity awards under the company’s Amended and Restated 2014 Equity Incentive Plan, and governance matters associated with the company’s corporate transition.
ChronoScale Corp director William M. Clancy has filed an initial Form 3 reporting his beneficial ownership position. The filing lists him as a director but does not report any stock transactions or derivative positions, indicating this is a baseline disclosure rather than a trading event.
ChronoScale Corp director William M. Clancy has filed an initial Form 3 reporting his beneficial ownership position. The filing lists him as a director but does not report any stock transactions or derivative positions, indicating this is a baseline disclosure rather than a trading event.
ChronoScale Corp director Richard N. Nottenburg has submitted a Form 3 initial statement of beneficial ownership. The Form 3 lists him as a director of ChronoScale but shows no reported transactions or share movements, with buy, sell, acquisition, and disposition counts all at zero.
ChronoScale Corp director Richard N. Nottenburg has submitted a Form 3 initial statement of beneficial ownership. The Form 3 lists him as a director of ChronoScale but shows no reported transactions or share movements, with buy, sell, acquisition, and disposition counts all at zero.
ChronoScale Corp director and Chief Executive Officer Chen Ying Cenly has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The data provided shows no reportable transactions or derivative positions, indicating this is a baseline disclosure of insider status rather than a trading event.
ChronoScale Corp director and Chief Executive Officer Chen Ying Cenly has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The data provided shows no reportable transactions or derivative positions, indicating this is a baseline disclosure of insider status rather than a trading event.
Ekso Bionics Holdings, Inc. reporting persons Armistice Capital, LLC and Steven Boyd amend a Schedule 13G/A to disclose beneficial ownership of 187,151 shares of Common Stock, representing 4.99% of the class as stated in Item 4. The filing identifies Armistice Capital as investment manager of the Master Fund and Mr. Boyd as its managing member. The ownership figures are presented in the filing with an as of reference to 03/31/2026 on the cover.
Ekso Bionics Holdings, Inc. reporting persons Armistice Capital, LLC and Steven Boyd amend a Schedule 13G/A to disclose beneficial ownership of 187,151 shares of Common Stock, representing 4.99% of the class as stated in Item 4. The filing identifies Armistice Capital as investment manager of the Master Fund and Mr. Boyd as its managing member. The ownership figures are presented in the filing with an as of reference to 03/31/2026 on the cover.
ChronoScale Corp (CHRN) Schedule 13G/A amendment reports that Mink Brook Partners LP and related entities held 0 shares of Common Stock as of the close of business on May 14, 2026. The filing disclaims beneficial ownership by Mink Brook Capital GP LLC and William Mueller except for any pecuniary interest.
ChronoScale Corp (CHRN) Schedule 13G/A amendment reports that Mink Brook Partners LP and related entities held 0 shares of Common Stock as of the close of business on May 14, 2026. The filing disclaims beneficial ownership by Mink Brook Capital GP LLC and William Mueller except for any pecuniary interest.
Applied Digital Corporation has taken control of ChronoScale Corporation (formerly Ekso Bionics) through a share exchange and a cash private placement. An Applied Digital subsidiary exchanged all 1,200 shares of Applied Digital Cloud Corporation for 138,216,820 ChronoScale common shares.
Applied Digital also bought 1,311,407 ChronoScale shares for $12.01 per share, totaling about $15.75 million. Following these transactions, it beneficially owns 139,528,227 shares, or 97.5% of ChronoScale’s outstanding common stock, making ChronoScale a Nasdaq-defined “controlled company.” An Investor Rights Agreement grants Applied Digital four of seven board seats, consent rights, preemptive rights and registration rights.
ChronoScale Corporation, formerly Ekso Bionics Holdings, completed its business combination with Applied Digital’s cloud subsidiary, Applied Digital Cloud Corporation, which is now a wholly owned subsidiary. The company also changed its name, fiscal year-end to May 31, and Nasdaq ticker to CHRN.
Contributor received 138,216,820 new common shares in exchange for all Cloud equity, and Applied Digital purchased 1,311,407 common shares for approximately $15.75 million in a private PIPE at $12.01 per share. After closing, Applied Digital and Contributor hold about 97% of outstanding common stock, leaving legacy Ekso holders with about 3% of 143,093,381 shares outstanding.
An Investor Rights Agreement gives Applied-related holders extensive board designation, observer, approval, preemptive and registration rights, while a services agreement entitles Applied Digital to a quarterly fee equal to 1% of ChronoScale’s gross revenue. The company adopted a 22,500,000-share 2026 Omnibus Equity Incentive Plan and appointed Ying Cenly Chen as CEO under a new offer letter, while changing auditors from WithumSmith+Brown to CBIZ CPAs.
Ekso Bionics Holdings, Inc. outlines the final steps to close its previously announced business combination with Applied Digital affiliates under a Contribution and Exchange Agreement, after which the company will be renamed ChronoScale Corporation and its stock is expected to trade on Nasdaq under the symbol “CHRN.”
As a condition to closing, Ekso entered into a Securities Purchase Agreement with Applied Digital Corporation for the APLD Parent PIPE Investment, selling 1,311,407 common shares at $12.01 per share for gross proceeds of about $15.75 million. Lake Street Capital Markets will receive a 5.0% cash fee, roughly $0.75 million, for placement services. The company also filed Second Amended and Restated Articles of Incorporation with effectiveness timed around the May 5, 2026 closing sequence.
Ekso Bionics Holdings, Inc. reported a sharp deterioration in results for the three months ended March 31, 2026 and raised substantial doubt about its ability to continue as a going concern. Revenue fell to $2,141 from $3,375, while net loss widened to $6,885 from $2,891, driven by lower device sales and higher general and administrative and sales and marketing costs.
Operating activities used $2,123 of cash, and cash and restricted cash totaled $3,993, with unrestricted cash around $3,743. Management currently estimates existing cash will fund operations only into the early part of the third quarter of 2026 and states it expects continued operating losses and negative operating cash flows.
To bolster liquidity, the company completed a January 2026 private placement of Series B Convertible Preferred Stock and warrants, generating net proceeds of about $5,265, and carries a $2,000 secured B. Riley promissory note and a $1,770 subordinated note to Parker Hannifin. New warrant liabilities of $2,863 were recorded at fair value, contributing to additional non‑cash expense.
Ekso Bionics Holdings, Inc. filed an amended annual report to add Part III disclosures, including director and executive biographies, compensation, ownership and auditor fee details, because a proxy statement will not be filed within 120 days. The amendment also updates the cover page, share count and includes refreshed CEO/CFO certifications.
As of April 2, 2026, Ekso had 3,563,381 common shares outstanding and a public float valued at $8.16 million as of June 30, 2025. In 2025, CEO Scott Davis received total compensation of $908,750, while the CFO and COO each earned under $500,000, with annual bonuses tied to revenue, cash spend and operational milestones. The company details board committee structures, independence determinations, equity incentive awards, change-in-control severance protections, a Dodd-Frank–compliant clawback policy and significant holders, including several institutions with more than 5% combined voting power.